Common Side Effects of Lurbinectedin
Lurbinectedin (brand name Zepzelca), approved for metastatic small cell lung cancer, frequently causes hematologic toxicities like neutropenia (57% of patients), anemia (53%), and thrombocytopenia (37%). Patients often experience fatigue (41%), nausea (39%), decreased appetite (35%), and musculoskeletal pain (33%). These occur mainly during the first cycle and are usually managed with dose adjustments or supportive care.[1][2]
Severe or Serious Risks
Myelosuppression can lead to febrile neutropenia (16%), pneumonia (13%), and sepsis (6%), sometimes requiring hospitalization. Liver enzyme elevations (ALT 27%, AST 25%) and hyperglycemia (13%) are notable. Rhabdomyolysis and tumor lysis syndrome are rare but reported. The drug carries a boxed warning for myelosuppression.[1][2][3]
How Side Effects Compare to Chemotherapy Alternatives
Compared to topotecan (a common small cell lung cancer treatment), lurbinectedin shows similar rates of severe neutropenia (51% vs. 64%) but lower severe anemia (15% vs. 51%) and thrombocytopenia (9% vs. 35%). Fatigue and nausea profiles align closely.[2][4]
Patient Management and Monitoring
Doctors recommend weekly complete blood counts for the first two cycles, then every other week, with delays or reductions for grade 3/4 cytopenias. Anti-emetics help nausea, and growth factors may address neutropenia. Effects typically resolve within weeks post-treatment.[1][3]
Long-Term or Less Common Effects
Peripheral neuropathy (12%), dyspnea (15%), and diarrhea (17%) appear less often. No unique cardiac toxicities stand out, but infusion reactions occur in under 2%. Real-world data confirm trial findings, with no new safety signals.[2][5]
Sources:
[1] Zepzelca Prescribing Information - FDA.gov
[2] IMagine-133 Trial (NEJM) - nejm.org
[3] NCCN Guidelines for Small Cell Lung Cancer - nccn.org
[4] Trigo et al. Lurbinectedin vs. Topotecan Meta-Analysis - PubMed
[5] FDA Post-Marketing Surveillance Summary - FDA.gov